Clinical Experience with Intraurethral Alprostadil (MUSE&lt;sup&gt;&amp;reg;&lt;/sup&gt;) in the Treatment of Men with Erectile Dysfunction

Guay, André T.; Perez, Jesús B.; Velásquez, Ernesto Lara; Newton, Roger G.; Jacobson, Jerilynn

doi:10.1159/000020360

Cited by 53 publications

(21 citation statements)

References 36 publications

(21 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The use of intraurethral alprostadil with similar overall efficacy rates to those reported in the general population of patients with ED has also been demonstrated in a range of special patient populations with specific ED risk factors, including those with diabetes, vascular disease, neuropathy, and alcohol/tobacco abuse [30,33,38,38,44], after surgery (e.g., radical prostatectomy [31,45,46,57]) or trauma (e.g., spinal cord injury [35]), and in patients with soft glans syndrome [37,47].…”

Section: In Special Patient Populationsmentioning

confidence: 75%

The role of intraurethral alprostadil as a first-choice erectile dysfunction treatment option in special populations: a proposed treatment algorithm

Dinsmore¹,

Lopes²,

Potempa³

et al. 2014

Clinical Practice

View full text Add to dashboard Cite

Section: In Special Patient Populationsmentioning

confidence: 75%

The role of intraurethral alprostadil as a first-choice erectile dysfunction treatment option in special populations: a proposed treatment algorithm

Dinsmore¹,

Lopes²,

Potempa³

et al. 2014

Clinical Practice

View full text Add to dashboard Cite

“…If not, it will increase the success rate of other therapies. In our clinic, we noted a 56% success rate with Medicated Urethral System for Erection (MUSE) 32 and an 82% success rate with sildenafil. 33 It is also to be remembered that failure with some treatments may indicate a low testosterone level, which will reverse when appropriately treated.…”

Section: Treatmentmentioning

confidence: 91%

Lecture 5

2001

Int J Impot Res

View full text Add to dashboard Cite

The incidence of diabetes mellitus is increasing at an alarming rate, and diabetic men already make up a quarter of the men in our own specific medically-oriented population of erectile dysfunction. The incidence of sexual dysfunction in men with diabetes approaches 50%, and this is only slightly lower in diabetic women. Hypertension is a frequent risk co-factor, being seen between 40% and 60% of diabetics in the literature. Obesity and hyperlipidemia are other frequent co-factors. Interestingly, these risk factors are the same as those for coronary artery disease. The final common pathway for most of these factors is endothelial cell dysfunction.

show abstract

“…20 While some men prefer intraurethral alprostadil over the injectable form, it is less effective, resulting in satisfactory erections in only 30-60 per cent of patients. [22][23][24] While penile pain is common 20 it is certainly less invasive than injections, and priapism and fibrosis are less common.…”

Section: Intraurethral Pelletmentioning

confidence: 99%

Management of erectile dysfunction in men treated with androgen deprivation therapy

Wilson

Atkinson

Hughes

2013

Trends Urol & Men's Health

View full text Add to dashboard Cite

A 55-year-old man presented to his GP with worsening pain in his left hip. The pain was present during the night as well as in the day. A plain radiograph of the hip demonstrated a sclerotic lesion suspicious of a metastatic deposit. Subsequent investigations revealed a prostate-specific antigen (PSA) of 200ng/ml. Similarly, sclerotic lesions were noted in the right hip and ischium. Prostatic biopsies confirmed Gleason 4+3 adenocarcinoma of the prostate and he was entered into the STAMPEDE trial. He was randomised to receive luteinising hormone-releasing hormone agonist therapy alone, so was commenced on goserelin injections. Bicalutamide was given at the beginning of therapy to prevent tumour flare. Six months later, his PSA had fallen to 0.6ng/ml with a serum testosterone <0.4ng/dl. During a clinic appointment he complained of loss of libido and difficulty maintaining erections adequate for sexual intercourse. He was commenced on tadalafil (Cialis) tablets twice a week as first-line treatment. THE CASEE rectile dysfunction (ED) is the persistent inability to attain and maintain a penile erection satisfactory for sexual intercourse. ED is increasingly common with advancing age, but is even more pronounced in men with prostate cancer who receive androgen deprivation therapy (ADT). Reported rates of impotence in this group range from 50 to 100 per cent.The aetiology of ED in men with prostate cancer is often mixed. Vascular and/or neurological damage at prostatectomy or following radical radiotherapy explains some of the incidence, but even without these treatments, such as in this case, erectile problems are common. Hormonal, neurological, vascular and psychological factors contribute to a greater or lesser degree in different individuals. EFFECTS OF ANDROGEN DEPLETIONAndrogen deprivation therapy, by definition, causes sustained suppression of serum In this series, the authors present cases of men being treated with androgen deprivation therapy, and highlight their management to prevent and treat associated toxicities. This second article will consider the management of erectile dysfunction.

show abstract

Clinical Experience with Intraurethral Alprostadil (MUSE<sup>®</sup>) in the Treatment of Men with Erectile Dysfunction

Cited by 53 publications

References 36 publications

The role of intraurethral alprostadil as a first-choice erectile dysfunction treatment option in special populations: a proposed treatment algorithm

The role of intraurethral alprostadil as a first-choice erectile dysfunction treatment option in special populations: a proposed treatment algorithm

Lecture 5

Management of erectile dysfunction in men treated with androgen deprivation therapy

Contact Info

Product

Resources

About